---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-24-000029"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:36:24.503281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aerovate reports Q1 2024 net loss $23.2M; cash $99.3M; Phase 2b topline data expected June 2024

## Summary
- Net loss of $23.2M for Q1 2024 vs $16.5M in Q1 2023; R&D expenses $20.1M, G&A $4.5M.
- Cash, equivalents and short-term investments $99.3M at March 31, 2024; raised net $23.6M via ATM in April.
- Topline data from Phase 2b portion of IMPAHCT trial of AV-101 in PAH expected in June 2024.
- Enrollment continues in Phase 3 portion of IMPAHCT; over 120 sites in 20+ countries.
- Cash runway into 2026 based on current operating plan.

## SEC filing metadata
- accession: 0001798749-24-000029
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/0001798749-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/tmb-20240513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-24-000029
- JSON: https://secwatch.observer/filing/0001798749-24-000029.json
- Plain text: https://secwatch.observer/filing/0001798749-24-000029.txt

## Key facts
- Earnings Releases
  Jade Biosciences, Inc. reported quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March.
  - Period: quarter ended March 31, 2024
  - Net income: Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March
  - Result: reported results
  source text: Net loss for the quarter ended March 31, 2024 was $23.2 million as compared to $16.5 million for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/0001798749-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.